Overview
Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients
Status:
Completed
Completed
Trial end date:
2017-02-02
2017-02-02
Target enrollment:
0
0
Participant gender:
All
All
Summary
Programmed ingestion of turmeric has no adverse effects and reduces plasma level of hs-CRP, IL-6 and TNF-α accompanying with increases albumin levels in hemodialysis patients. Turmeric can be considered as an effective anti-inflammatory supplement in hemodialysis patients.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Shahid Beheshti University of Medical SciencesTreatments:
Curcumin
Criteria
Inclusion Criteria:• Males or females undergoing maintenance hemodyalisis,- Age ≥18 year
- Clinically stable and receiving adequate hemodialysis defined by a single pool
Kt/V≥1.20 or no less than 3 dialysis sessions per week with a total dialysis time ≥12
hour per week for at least 3 month before enrollment,
- Diabetic patients must be willing to commence insulin therapy if deemed necessary for
plasma glucose control.
Exclusion Criteria:
- Active malignant disease (defined as less than 5 year since receiving a diagnosis of
being malignancy-free)
- Critical illness as defined by the need for respiratory or circulatory support
(in an intensive care unit)
- Active vasculitis
- Severe congestive heart failure (New York Heart Association class IV)
- Severe chronic systemic infectious or inflammatory disease
- Liver disease (defined as serum alanine aminotransferase or aspartate
aminotransferase levels greater than three times the upper limit of normal)
- Known or suspected allergy to trial product(s) or related products
- Treatment with immunosuppressive agents or receipt of any investigational drug
within one month preceding screening
- Recent or current use of anti-inflammatory corticosteroids agents
- A scheduled renal transplantation within the trial period